Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
about
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsRecent developments and translational aspects in targeted therapy for metastatic breast cancerUnveiling changes in the landscape of patient populations in cancer early drug developmentTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors.Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristicsTreatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell PopulationMosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Emerging therapeutic targets in metastatic progression: A focus on breast cancer.FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell CarcinomaCharacterization of FGFR signaling pathway as therapeutic targets for sarcoma patientsIntegrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Best practice in the treatment of advanced squamous cell lung cancer.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.Precision medicine for metastatic breast cancer--limitations and solutions.Targeting FGFR in Squamous Cell Carcinoma of the Lung.Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?FGFR-targeted therapeutics for the treatment of breast cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.FGFs: crucial factors that regulate tumour initiation and progression.The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia.Advances and challenges in targeting FGFR signalling in cancer.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment.An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.Relevance of genetic alterations in squamous and small cell lung cancer.Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
P2860
Q26801718-07909420-71EE-4F81-B4A0-3C63F0B95C8FQ28072755-A3D7A51C-D0FD-4425-9193-F192576C4097Q28073826-F1D8D3DE-8E4F-4B24-838D-E00F56A49864Q28085062-245421D2-1C8A-4A6F-B3CA-540A3FAA3CC8Q35496344-D45FC8C9-4726-4630-8D25-6B76B2BEDD88Q35751428-9F9FE558-A30F-4889-B5A5-3B46476DAEE9Q35836960-3B201F48-EC61-4534-B02B-A434FB969455Q35944914-26CC6F81-B955-4A47-B808-EA65BD7D7E42Q36189141-6D7DC394-A8AF-4893-895A-0CAFDFACEF29Q36471425-4F58E6C4-8457-4A20-A4E0-B6B0A10D66ECQ36707108-18180EBC-8222-4402-AF22-E67F7440EC79Q36811784-5382D074-73F0-43D2-AF0F-5E4D8553E71AQ36854062-833959B9-BF3A-49E1-922A-23B7942FBBE8Q37067161-7F2686DB-C483-4D63-BC2C-906868C7302AQ37094042-275E1684-1D1E-4B57-B123-F9D5D9365FB0Q37212868-6FDD90DF-7694-48AB-BE30-E1A4A0B3B665Q37515231-B0DF9D78-7CC2-43FC-B6C5-4F962B0EEC9DQ37721218-081FA533-8570-4EA8-85AB-767FF1DF4C99Q38435967-3C851E25-2402-4274-BCFE-0DCCF6FFD53DQ38525073-6F9496D8-2E38-4DDC-ABF6-98EDF9F8F8D2Q38540713-6FA21F8B-E487-4EA6-BDAC-8FFB6130ED36Q38551394-84D43033-1BBE-4024-B24C-A515D55EF547Q38690050-6535A708-DE54-4CBD-9DED-345D735BB1CEQ38714068-71138385-1226-40DD-B003-5A5176D80C27Q38741697-F7BD8F5D-35A8-410C-92BD-A5339A7A844AQ38766035-C918E19B-445C-4214-A489-59C1216963BEQ38784119-FF468B0A-81C3-418A-9CAB-AAA0A89DAF5FQ38825945-C792CD71-5FDD-4351-A436-83648456E5C8Q38887615-448F129F-0D5B-4337-A60D-D63ABE5F2E10Q39172384-1444B884-351D-4E6E-A274-FE433E82E103Q39183442-23F8BF59-3327-4184-A57B-07703E8EA959Q39226762-3DF9FE79-0AAE-4B59-A24D-7DDAF2DBA922Q39282670-B38786F7-4ABC-4736-B905-990EFF3F45E3Q40417660-B446394D-8E92-45EA-860C-6C7AAC555338Q40814170-9EED15D2-3950-4476-8D10-6E0E6F13DD7CQ42320235-29107A29-C7C9-4179-818A-BC982AAE7A3BQ44483486-9664B9AD-2796-4FF7-94F6-2D572D41F39FQ44643445-1C79B864-A374-40B3-99E9-AE1E7B5B0829Q45069154-ED66AE06-FFD2-4626-AE7E-D2525293C388Q45992368-AB8F0A70-C93D-4EC0-BC85-217C28DB02F7
P2860
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@ast
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@en
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@nl
type
label
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@ast
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@en
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@nl
prefLabel
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@ast
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@en
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Phase I/IIa study evaluating t ...... tanib in advanced solid tumors
@en
P2093
J Isaacson
M G Camboni
P2860
P304
P3181
P356
10.1093/ANNONC/MDU390
P407
P577
2014-11-01T00:00:00Z